Redburn Atlantic Raises Price Target on Insulet to $300 From $270, Keeps Buy Rating
Insulet Is Maintained at Overweight by JP Morgan
Insulet Analyst Ratings
J.P. Morgan Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $330
Morgan Stanley Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $317
Insulet's Strong International Performance and Optimistic Type 2 Diabetes Market Outlook Drive Positive Analyst Rating
Citigroup Raises Price Target on Insulet to $310 From $283, Keeps Buy Rating
Insulet Is Maintained at Overweight by Wells Fargo
Insulet Analyst Ratings
Citi Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $310
Wells Fargo Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $305
Wells Fargo Keeps Their Buy Rating on Insulet (PODD)
Jefferies Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $340
Insulet (PODD) Receives a Buy From Jefferies
Insulet Is Maintained at Buy by Canaccord Genuity
Insulet Analyst Ratings
CCORF Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $304
Wells Fargo Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $290
Analysts' Top Healthcare Picks: Insulet (PODD), Monte Rosa Therapeutics (GLUE)
Morgan Stanley Sticks to Their Buy Rating for Insulet (PODD)